文献速递肝病消化道肿瘤与早癌

ADP-A2AFP TCR T细胞疗法治疗晚期肝癌或胃肝样腺癌的I期试验

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
PubMed 文献 · J Hepatol · 2025-08-12

所有患者发生≥3级不良事件,52.4%发生治疗相关≥3级事件,6例发生细胞因子释放综合征。客观缓解率9.5%,1例完全缓解、1例部分缓解、12例疾病稳定。

要点

  • ADP-A2AFP TCR T细胞疗法在经治晚期肝癌中安全性可控。
  • 客观缓解率9.5%,含1例完全缓解和1例部分缓解。
  • 治疗后肿瘤样本AFP阳性区域可见TCR和CD8+ T细胞浸润。

核心结论

  • 淋巴细胞清除化疗后输注ADP-A2AFP TCR T细胞在经治晚期肝癌患者中安全性可控,并显示初步抗肿瘤活性。

研究设计与样本

  • I期开放标签首次人体临床试验(NCT03132792),纳入HLA匹配且表达AFP的肝癌或其他肿瘤患者,不接受移植或切除且既往系统治疗进展、不耐受或拒绝。
  • 输注前接受淋巴细胞清除化疗:环磷酰胺500 mg/m2/天×3天联合氟达拉滨20 mg/m2/天×3天,或环磷酰胺600 mg/m2/天×3天联合氟达拉滨30 mg/m2/天×4天。

主要发现

  • 所有参与者发生至少1项≥3级不良事件,52.4%发生至少1项研究者认为与ADP-A2AFP治疗相关的≥3级事件。
  • 6例发生细胞因子释放综合征(1-2级5例,4级1例)。
  • 最佳总体疗效:完全缓解1例、部分缓解1例、疾病稳定12例,客观缓解率9.5%。
  • 8例患者疾病稳定持续时间≥16周。
  • 治疗后肿瘤样本AFP阳性区域可见ADP-A2AFP TCR和CD8+ T细胞浸润;缓解者中ADP-A2AFP剂量增加与血清AFP下降相关。

关键数值与推荐

  • 安全性为主要终点,RECIST v1.1评估的疗效为关键次要终点。

临床怎么用

  • ADP-A2AFP TCR T细胞疗法可能成为晚期肝癌经治患者的一种额外治疗选择,但需进一步研究验证。

局限性

  • I期小样本首次人体试验,安全性及初步疗效需在更大样本中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with advanced hepatocellular carcinoma (HCC) generally experience poor outcomes despite current therapies, necessitating the development of alternative treatments. ADP-A2AFP is an investigational autologous T-cell therapy with an affinity-enhanced T-cell receptor (TCR) targeting alpha-fetoprotein (AFP). METHODS: We describe a phase I, open-label, first-in-human clinical trial of ADP-A2AFP (NCT03132792) in human leukocyte antigen-eligible participants with AFP-expressing HCC (or other tumor) not amenable to transplant/resection who progressed on, were intolerant to, or refused prior systemic therapy. Participants received lymphodepletion chemotherapy (cyclophosphamide 500 mg/m2/day for 3 days and fludarabine 20 mg/m2/day for 3 days, or cyclophosphamide 600 mg/m2/day for 3 days and fludarabine 30 mg/m2/day for 4 days) followed by ADP-A2AFP intravenous infusion. Safety evaluation was the primary objective; response per RECIST v1.1 was the key secondary endpoint. RESULTS: Twenty-one participants, 20 with advanced HCC and one with gastric hepatoid carcinoma received ≥1 ADP-A2AFP infusion. All participants experienced ≥1 grade 3 or higher adverse event; 52.4% experienced ≥1 grade 3 or higher event considered related to ADP-A2AFP treatment. Six participants experienced cytokine release syndrome (grade 1-2: n = 5; grade 4: n = 1). Best overall responses were complete response (n = 1), partial response (n = 1), and stable disease (n = 12); overall response rate was 9.5%. Eight patients had a stable disease duration of ≥16 weeks. Infiltration of ADP-A2AFP TCR and CD8+ T cells was seen in AFP-positive areas of post-treatment tumor samples. A relationship was demonstrated between increased ADP-A2AFP dose and serum AFP reduction in responders. CONCLUSIONS: Lymphodepletion chemotherapy followed by ADP-A2AFP TCR T-cell therapy showed a manageable safety profile and preliminary indications of antitumor activity in these previously treated patients. IMPACT AND IMPLICATIONS: Adoptive T-cell therapy could be a much-needed additional treatment strategy for advanced hepatocellular carcinoma. Clinicians and researchers interested in the development of adoptive T-cell therapies for advanced solid tumors will be interested to learn that in this phase I trial, ADP-A2AFP T-cell receptor T-cell therapy was associated with an acceptable benefit-to-risk profile and encouraging antitumor activity, illustrating the treatment potential of adoptive T-cell therapy for advanced hepatocellular carcinoma. GOV NUMBER: NCT03132792; first posted 2017-04-08.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Meyer T, Finn RS, Borad M, et al. Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma. J Hepatol. 2025. PMID: 40812667. doi:10.1016/j.jhep.2025.07.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。